Biased Agonism in Drug Discovery—Is It Too Soon to Choose a Path?

Martin C. Michel and Steven J. Charlton

Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany (M.C.M.); Department of Life Sciences, University of Nottingham, Nottingham, United Kingdom (S.J.C.); and Excellerate Biosciences Ltd., MediCity, Nottingham, United Kingdom (S.J.C.)

Received October 20, 2017; accepted January 1, 2018

ABSTRACT

A single receptor can activate multiple signaling pathways that have distinct or even opposite effects on cell function. Biased agonists stabilize receptor conformations preferentially stimulating one of these pathways, and therefore allow a more targeted modulation of cell function and treatment of disease. Dedicated development of biased agonists has led to promising drug candidates in clinical development, such as the G protein-biased μ opioid receptor agonist oliceridine. However, leveraging the theoretical potential of biased agonism for drug discovery faces several challenges. Some of these challenges are technical, such as techniques for quantitative analysis of bias and development of suitable screening assays; others are more fundamental, such as the need to robustly identify in a very early phase which cell type harbors the cellular target of the drug candidate, which signaling pathway leads to the desired therapeutic effect, and how these pathways may be modulated in the disease to be treated. We conclude that biased agonism has potential mainly in the treatment of conditions with a well-understood pathophysiology; in contrast, it may increase effort and commercial risk under circumstances where the pathophysiology has been less well defined, as is the case with many highly innovative treatments.

INTRODUCTION

It has been assumed historically that a given G protein-coupled receptor (GPCR) primarily couples to one G protein and signaling pathway—for instance, angiotensin II type 1 receptors (AT1Rs), muscarinic M3 receptors, and α1-adrenoceptors receptors couple to Gq; muscarinic M2 receptors, μ opioid receptors and α2-adrenoceptors couple to Gi; and β-adrenoceptors couple to Gs (Bylund et al., 1994; Dhawan et al., 1996; Caulfield and Birdsall, 1998; de Gasparo et al., 2000). While exceptions to this rule were reported not too long after the definition and classification of G proteins, it has only become accepted in the past decade that coupling of a single GPCR to multiple G proteins is the rule and not the exception. Receptors typically coupling to Gq proteins can also couple to Gi proteins, for instance, AT1R (Crawford et al., 1992), or to Gs proteins, for instance, α1B-adrenoceptors (Horie et al., 1995). Conversely, typically Gi-coupled receptors such as M2 muscarinic acetylcholine receptors can also couple to Gs (Schmidt et al., 1998), and typically Gs-coupled receptors such as β2- and β3-adrenoceptors can also couple to Gi (Cao et al., 2000) and/or Gq (Wenzel-Seifert and Seifert, 2000). Moreover, GPCRs can directly couple not only to G proteins but also to other signaling molecules such as arrestins (Peterson and Luttrell, 2017) or src (Cao et al., 2000). Apparently, the classic or canonical signaling pathway of a receptor is present in most if not all cell types, whereas the additional or noncanonical signaling pathways can exhibit a more restricted presence. For instance, we have detected coupling to cAMP formation upon β-adrenoceptor stimulation, presumably via Gs, in every cell type we ever studied; in contrast, we only detected coupling to phosphorylation of extracellular signal-regulated kinase (ERK) via Gi in only some cell types. This does not necessarily mean that coupling to additional signaling pathways per se is restricted, but it may be too weak in many cell types to be quantified in a robust manner.

The term biased agonism, originally introduced by Jarpe et al. (1998), describes the phenomenon that a ligand preferentially activates one of several signaling pathways, whereas the Deutsche Forschungsgemeinschaft (Mi 294/8-1) and Velicept Therapeutics.

M.C.M. is a former employee of Boehringer Ingelheim. He also has received consultancy honoraria from Dr. Wilmar Schwabe and Velicept Therapeutics, and is a shareholder of the latter company. S.J.C. is a founding Director and Chief Scientific Officer of Excellerate Bioscience, and a former employee of Novartis.

The work in the laboratory of M.C.M. has been or presently is supported by the Deutsches Forschungsgemeinschaft (Mi 294/8-1) and Velicept Therapeutics. ABBREVIATIONS: AT1R, angiotensin II type 1 receptor; ERK, extracellular signal-regulated kinase; GPCR, G protein-coupled receptor; JNJ7777120, 1-[[5-chloro-1H-indol-2-yl]carbonyl]-4-methylpiperazine; OAB, overactive bladder; PTX, pertussis toxin; TPP, target product profile; TRV 027, N-methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-D-alanine.
another agonist in the same system and acting on the same receptor preferentially activates another pathway (Patel et al., 2010). This phenomenon has also been referred to as stimulus trafficking (Kenakin, 1995), functional dissociation (Whistler et al., 1999), biased inhibition (Kudlacek et al., 2002), differential engagement (Manning, 2002), and ligand-directed signaling (Michel and Alewijnse, 2007). Such preferential coupling translates into differential induction of receptor trafficking and gene transcription programs (Maudsley et al., 2015; Delgado-Peraza et al., 2016). Of note, the concept of biased agonism is not necessarily restricted to GPCRs and could also be applied to other signaling processes where the ligand-activated molecule may bind to more than one partner, for instance, to steroid hormone receptors and other ligand-activated transcription factors (Michel et al., 2014).

Perhaps the best-known hypothesis for the molecular basis of biased agonism relates to the fact that each ligand stabilizes a specific conformation of a receptor (Kenakin and Morgan, 1989; Kenakin and Miller, 2010; Costa-Neto et al., 2016). This has been demonstrated using a variety of techniques, from NMR and double electron-electron resonance spectroscopy (Manglik et al., 2015) to stabilization of discrete conformations using allostERIC nanobodies (Staus et al., 2016). Since different receptor conformations are likely to exhibit different affinities for various G proteins or G protein versus arrestin, it appears logical that ligands inducing different receptor conformations will also differentially affect coupling to specific G proteins, i.e., can exhibit biased agonism. Even minor chemical differences between ligands, e.g., their stereoisomers, may lead to preferential activation of distinct signaling pathways of the same receptor (Seifert and Dove, 2009). A structural basis for this is that distinct amino acids within a receptor are critical for coupling to G_s compared with G_i proteins (Manglik et al., 2015).

Many cases of proposed biased agonism include receptor binding to arrestins (Peterson and Luttrell, 2017), which in turn is often linked to activation of ERK (Patel et al., 2010; Szakadáti et al., 2015; Delgado-Peraza et al., 2016). Activation of ERK can also occur independently of arrestin, for instance, via src (Cao et al., 2000). Moreover, it has been proposed that receptors primarily coupling to G_s or G_i proteins may activate ERK via G_i. An example of the latter are β_3-adrenoceptors, which typically couple to G_i followed by activation of adenylyl cyclase and generation of cAMP; however, in some cell types they can also cause (moderate) induction of ERK phosphorylation, which is proposed to involve activation of a pertussis toxin (PTX)–sensitive G protein, presumably G_i (Gerhardt et al., 1999; Söder et al., 1999). However, the latter finding may not be robust since it is based on the observation that less ERK phosphorylation was observed following pretreatment with PTX, but the effects of PTX on basal ERK phosphorylation had not been assessed. Recent observations from our group confirm that PTX reduces ERK phosphorylation responses but also markedly lowers basal ERK phosphorylation; relative to this lowered basal value, β_3-adrenoceptor ligands, if anything, yielded a greater relative enhancement of ERK phosphorylation than in the absence of PTX (Okeke et al., 2018). Since this may also apply to other receptors, the true role of G proteins in ERK activation as an alternative signaling pathway remains to be determined. Of note, ERK activation by G_s- or G_i-coupled receptors may result from activation of these G proteins (Lefkowitz et al., 2002).

Based on the molecular basis of biased agonism, the specific signaling pathway activated by a ligand depends on several factors (Kenakin and Christopoulos, 2013). First, the bimolecular interaction between ligand and receptor favors a specific receptor conformation. This conformation in turn will favor binding to a given G protein, arrestin, or other signaling molecule. These two properties together define ligand bias (Kenakin, 2015a). Second, the stochiometric ratio of G proteins, arrestins, and other signaling partners affects the degree to which they will be activated by a given receptor conformation (Onfroy et al., 2017). Thus, high expression of one signaling partner may lead to preferential activation of this pathway even if the receptor conformation has somewhat lower affinity for it. These stochiometric ratios define system bias (Kenakin, 2015a). Third, stochiometric ratios of G proteins and arrestins in a given cell type or tissue can be modified by various physiologic, pathologic, or iatrogenic factors. These effects define dynamic bias (Michel et al., 2014). Fourth, whether a given signaling pathway is stimulated by a ligand may be dominated by the intrinsic efficacy of that ligand for the pathway to be activated, which in turn depends on the relative affinity of the effector molecules for the receptor (Kenakin, 2015b). Of note, ligands may be weak partial agonists or even inverse agonists for one signaling pathway but strong agonists for another signaling pathway, for instance, carvedilol at β_3-adrenoceptors (Wisler et al., 2007) or L 748,337 at β_3-adrenoceptors (Sato et al., 2008).

The Promise of Biased Agonism

Since different G proteins and arrestins can modulate different signaling pathways, which in some cases may even have opposite effects on cell function, it is obvious that a ligand exhibiting biased agonism may yield distinct cellular responses compared with a reference agonist. Some of these signaling responses may be desirable, whereas others are undesirable depending on the clinical condition under consideration. Thus, biased agonism in principle offers the possibility to selectively modulate one cellular/tissue response activated by a given receptor. For obvious reasons, this potential new avenue for selective modulation of cell and tissue function has generated considerable excitement.

The most informative example, and perhaps up to now the only example, of how the potential of biased agonism can be leveraged for the development of novel therapeutics is the discovery of opioid receptor agonists that exhibit analgesic effects but are associated with little constipation and/or respiratory suppression. Initial work had demonstrated that β-arrestin 2 knockout mice or mice and rats injected with β-arrestin 2 interfering RNAs exhibited enhanced analgesia in response to opioid receptor agonists but less tolerance development and little constipation or respiratory suppression (Raehal et al., 2011; Kelly, 2013). This suggested that µ opioid receptor agonists biased for G protein activation, but having little arrestin-mediated effects, may exhibit a beneficial profile in the treatment of pain. Based on such findings, a team at Trevena has developed oliceridine (formerly known as TRV 130), a µ opioid receptor agonist (DeWire et al., 2013). Oliceridine exhibited robust G protein activation with a potency and efficacy similar to that of morphine, but caused far less arrestin recruitment and receptor internalization. It was a potent analgesic in mice and rats but caused less...
gastrointestinal dysfunction and respiratory suppression than morphine at equally analgesic doses. A clinical phase II study confirmed that oliceridine is a potent analgesic drug in patients (Viscusi et al., 2016), and the Food and Drug Administration has granted breakthrough therapy status to this drug. Oliceridine produced similar analgesia compared with morphine but caused fewer adverse events in a phase IIb study (Singla et al., 2017). However, presently available clinical data rely on short-term administration, i.e., are unsuitable to determine whether the reduced desensitization, constipation, and respiratory depression also occur with chronic treatment. In a different approach, other investigators have used the crystal structure of μ opioid receptors and docking studies with over three million molecules to identify another ligand with strong bias for the G protein compared with arrestin pathways (Manglik et al., 2016); however, the leading ligand identified in this study has not yet been tested clinically. Biased agonists have also been described for κ opioid receptors (White et al., 2014), but the relevance for this subtype in analgesia remains unclear.

The Unfulfilled Promise of Biased Agonism

AT1Rs are modulators of many cardiovascular and renal functions; antagonists at these receptors have beneficial effects in corresponding disease and are clinically established drugs (Michel et al., 2016) but the clinically used AT1R antagonists do not exhibit biased agonism (Michel et al., 2013). However, experimental AT1R antagonists (Szakadáti et al., 2015) and analogs of the endogenous agonist angiotensin II (Domazet et al., 2015) exhibit biased agonism. Therefore, investigators at Trevena also developed biased agonists at AT1R. They reasoned that the optimal ligand should be a potent antagonist for G protein activation via AT1R but a biased agonist promoting arrestin recruitment. Based on these considerations, they have identified N-methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-D-alanine (TRV 027) (formerly known as TRV 120027). It was found that TRV 027 inhibited angiotensin-stimulated G protein signaling and stimulated arrestin recruitment and activated several kinase pathways, including ERK, src, and endothelial nitric oxide synthase phosphorylation (Violin et al., 2010). Similar to clinically used AT1R antagonists, TRV 027 reduced blood pressure, but unlike the unbiased antagonists it increased cardiac performance. This compound showed promising results in a dog model of congestive heart failure (Boerrigter et al., 2012). However, this clinical phase II study (i.e., the BLAST-AHF study; see Pang et al., 2017) failed to meet its composite primary endpoint consisting of the following: 1) time from baseline to death through day 30; 2) time from baseline to heart failure rehospitalization through day 30; 3) the first assessment time point following worsening heart failure through day 5; 4) change in the dyspnea visual analog scale score calculated as the area under the curve representing the change from baseline over time from baseline through day 5; and 5) length of initial hospital stay (in days) from baseline (Pang et al., 2017).

Many reasons may potentially explain why a novel drug fails to reach its primary endpoint in a clinical proof-of-concept study. However, it is noteworthy that the clinically most advanced drug candidate based on biased agonism is an agonist at μ opioid receptors. This is a mechanism of action that has been known for more than a century and numerous clinical and preclinical investigations have elaborated on the properties of morphine and how it decreases pain, causes tolerance, and induces constipation and respiratory depression. Thus, the analgesic properties of opioid receptor agonists may be one of the best understood mechanisms in all of pharmacology. This is not likely to be the case for drug candidates that are based on novel targets.

The Challenge for Drug Discovery

Two technical obstacles exist for leveraging the promise of biased agonism for drug discovery. First, quantification of bias is not a trivial thing. Several useful approaches have been developed (Kenakin, 2015b; Luttrell et al., 2015; Stott et al., 2016; Gundry et al., 2017; Onaran et al., 2017), with Δlog(EC_{50}) (K_{a}) or Δlog(E_{\text{max}}/EC_{50}) being perhaps the most useful tools currently available (Winpenny et al., 2016). However, it has recently been demonstrated that the kinetic context at the level of ligand-receptor and receptor-pathway kinetics is also a key consideration, which further complicates the interpretation of data (Klein Herenbrink et al., 2016; Lane et al., 2017). Identification of suitable screening assays for biased agonism, particularly high-throughput assays, is not trivial either, but there is theory to address this (Luttrell et al., 2015) and examples of practical implementation (Winpenny et al., 2016; McAnally et al., 2017). For reasons of scope, these obstacles will not be discussed further here.

In our view, the biggest challenge for drug discovery based on biased agonism is establishing the correct target product profile (TPP), which is used to determine how effective the ligand to be developed should be for each signaling pathway. We illustrate this challenge largely based on the example of drug discovery for β_{3}-adrenoceptor agonists, a novel drug class for the treatment of the overactive bladder (OAB) syndrome (Ohlstein et al., 2012; Chapple et al., 2014).

The signaling response to a receptor ligand depends on a combination of factors attributable to the ligand and the cell type/tissue in which it acts (ligand and system bias, respectively) (Kenakin, 2015a), and any changes this system may undergo in a pathologic setting (dynamic bias) (Michel et al., 2014). Thus, the TPP of the lead compound for development must make assumptions about which cell type harbors the molecular target responsible for desired and potential adverse effects, which signaling pathways mediate such effects, and how this may be modulated in disease. Most β_{3}-adrenoceptor agonists that have entered clinical development originally had been selected for the treatment of type 2 diabetes and obesity at a time when little knowledge was available about biased agonism and its implications; development for OAB syndrome was a repurposing endeavor (Michel and Korstanje, 2016). When repurposing studies for the OAB syndrome indication began, it had been assumed that the cellular target is the smooth muscle cell in the urinary bladder detrusor and that it mediates its desirable effects by increasing intracellular cAMP concentrations. Therefore, primary and secondary screens for suitable compounds in various companies were based on cAMP generation and relaxation of isolated detrusor strips in an organ bath, respectively, for instance, for mirabegron (Takasu et al., 2007), ritobegron (Maruyama et al., 2012), solabegron (Hicks et al., 2007), and vibegron (Moyes et al., 2017). While one of these compounds has successfully
undergone clinical development (Chapple et al., 2014) this may have been pure luck. Thus, while such drugs were already in clinical development, it became clear that cAMP generation plays a minor role (if any role at all) in mediating detrusor smooth muscle relaxation by β-adrenoceptor agonists (Frazier et al., 2005; Uchida et al., 2005). Perhaps even more importantly, it is now increasingly being questioned whether the detrusor smooth muscle cell is indeed the cellular target of this drug class or rather is indirectly modulated via the urothelium, afferent nerves, or other structures (Michel, 2015). Therefore, even with today’s knowledge it is difficult to say which cell type (system bias) and which signaling pathway (ligand bias) would be the optimal target for the treatment of OAB syndrome.

Moreover, β2-adrenoceptor ligands for the treatment of OAB syndrome must be agonists, and based on their mode of action are assumed to provide symptom relief but not cure, indicating that long-term treatment may be required. Desensitization is a general issue with extended treatment with GPCR agonists, and biased agonism may affect speed and extent of desensitization (Raehal et al., 2011), including those of β-adrenoceptors (Gimenez et al., 2015). Therefore, it would be interesting to know whether the β3-adrenoceptor agonists used or intended for use in OAB syndrome treatment differ with regard to biased agonism and how this affects their susceptibility for desensitization. Whether any of the clinically tested β3-adrenoceptor agonists is a biased agonist remains unknown, but multiple experimental β2-adrenoceptor ligands are biased agonists (Evans et al., 2010). However, recent data show that both cAMP formation and ERK phosphorylation can undergo agonist-induced desensitization when expressed in Chinese hamster ovary cells, but that the pattern of desensitization differs between the two signaling pathways (Okeke et al., 2018).

The aforementioned may be a rather theoretical example since effective drugs have emerged. However, it illustrates how lack of pathophysiological knowledge increases risk in defining a TPP. If neither the cell type nor the signaling pathway leading to desired therapeutic effect is known with certainty, it remains a high-stakes gamble to define the desirable molecular properties of a drug development candidate, i.e., whether it should be a biased agonist, and if so for which signaling pathway. Only early translational approaches (most likely based on animal models) will be able to test whether a TPP based on biased agonism is viable. Strategies for translational pathway validation have been reported (Rominger et al., 2014) but do not address the validity of the inherent assumptions about validity of the model being used for the human target tissue and its alterations in disease.

Animal models still play a key role in target validation activities for many disease states, particularly through the widespread use of knockout mouse models. It is not common, however, for the degree of agonist bias to be studied at different species orthologs of the human receptor. The often tacit assumption that the pathway bias of a particular compound is maintained in other species presents another potential risk when ascribing the required degree of bias for a particular disease. This can be exemplified by studies on the histamine H4 receptor. 1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ7777120) was the first selective histamine H4 antagonist described and has been critical in defining a role for the H4 receptor in a variety of allergic and inflammatory processes (Thurmond et al., 2008). In 2011, however, it was discovered that although JNJ7777120 was an antagonist/inverse agonist at the human H4 receptor–mediated Gs pathway, it was a partial agonist for the recruitment of β-arrestin to the human H4 receptor (Rosethorne and Charlton, 2011). Furthermore, it was able to induce prolonged ERK activation. While this unexpected biased agonism at the human receptor clearly complicates the interpretation of previous studies that assumed pure antagonism, the waters were muddied further when the activity of JNJ7777120 was tested in a number of species orthologs of the H4 receptor. Surprisingly, and in stark contrast to the human receptor, JNJ7777120 was a partial agonist at the Gs pathway from the mouse, rat, and dog H4 receptor (Schnell et al., 2011). This suggests that the beneficial effects of JNJ7777120 in the mouse (Thurmond et al., 2004) may be via H4-mediated Gs activation, rather than inhibition, potentially leading to the wrong choice of pathway for treating human disease. These species differences also raise concerns over interpretation of safety studies that often use the rat and dog as preferred species for the evaluation of toxicology. Thus, biased agonism simply being a probe-dependent form of allosterism and allosteric effects being species dependent, it should not be surprising that biased agonism observed in one species does not necessarily translate to others.

System bias (i.e., the stoichiometric ratios between relevant signaling molecules) and dynamic bias (i.e., their possible alterations in disease and/or with treatment) are key in establishing the optimal TPP. As indicated previously, the signaling pathway being activated by a ligand depends on its intrinsic properties (ligand bias) and those of the cell type that is targeted (system bias). A key element that influences system bias is the stoichiometric ratio of the different signaling molecules that are able to bind to activated receptor conformations (Onfroy et al., 2017), which is likely to differ considerably between cell types and tissues. To highlight this point, we have analyzed data on mRNA expression of several thousand genes across a panel of 31 human tissues (Uhlén et al., 2015). This analysis shows that the ratio between expression of Gαs, Gαi, and arrestin is highly variable between tissues (Fig. 1). While these data are based on mRNA expression and we do not know how this translates into functional protein in those tissues, it is safe to assume that a similar lack of correlation will hold true at the protein level and also when cell types rather than tissues are analyzed. Moreover, if differential expression of these three elements exists across human tissues, it is likely that similar differential expression exists in animal models compared with patients.

To further complicate matters, expression of these various signaling components within a given cell type of tissue can be modulated by disease. For instance, congestive heart failure (the condition in which TRV 027 did not meet its primary endpoint) is characterized by desensitization and downregulation of β1-adrenoceptors (with less, if any, desensitization and downregulation of β2-adrenoceptors), downregulation of Gαs, and upregulation of Gαi-β-arrestin-1, and G protein-coupled receptor kinases (Brodde, 2007). Thus, a signaling pathway that may have been important in healthy tissue may be less or more prominent in disease tissue. We have proposed to call such alterations of the signalosome dynamic bias (Michel et al., 2014).
of the kinetics and signal strength to a particular phenotypic response. Förster resonance energy transfer–based imaging biosensors have been developed that can monitor the spatiotemporal characteristics of signaling pathways (e.g., calcium, cAMP, and phosphorylated ERK) in single cells and even subcellular compartments (Lohse et al., 2012; Halls et al., 2015). More exciting still is the recent use of genetically encoded versions of these sensors to measure spatiotemporal signaling at the whole organ level in living animals (van Unen et al., 2015; Jones-Tabah et al., 2017).

Using a microendoscopic implant, signaling via protein kinase A and ERK1/2 has been imaged in the striatum of mice undergoing behavioral testing (Goto et al., 2015; Yamaguchi et al., 2015), representing a step change in our ability to monitor therapeutically relevant signaling pathways in their physiologic context.

The concomitant coupling of a single receptor to multiple signaling pathways and the selectivity for one of them that can theoretically be achieved by biased agonists is an attractive concept for drug discovery. However, definition of a sound TPP requires a lot of assumptions on system bias and dynamic bias, most importantly the cell type mediating the desired response and adverse responses, the signaling pathway causing them, and how they behave quantitatively in the disease to be treated. Since such knowledge typically is not available for highly innovative targets at the time lead identification and optimization takes place, we feel that targeted development of biased agonists will be limited to a rather small number of conditions, and even then only in the discovery of second or third generation medicines.

**Acknowledgments**

The authors thank Deutsche Forschungsgemeinschaft (Mi 294/8-1) and Velicept Therapeutics for the financial support given for work in the authors’ laboratories.

**Authorship Contributions**

- **Participated in research design:** Michel, Charlton.
- **Performed data analysis:** Michel, Charlton.
- **Wrote or contributed to the writing of the manuscript:** Michel, Charlton.

**References**


Address correspondence to: Martin C. Michel, Department of Pharmacology, Johannes Gutenberg University, Obere Zahlbacher Strasse, 67, 55131 Mainz, Germany. E-mail: marmiche@uni-mainz.de